title: Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
abstract: Several studies have shown reduction of visceral adipose tissue (VAT) using recombinant human growth hormone (r-hGH) in HIV-1+ patients, but whether these effects are maintained after the end of treatment is unknown. In a prospective, randomized study we previously studied the effects of r-hGH 4 mg daily vs 3 times/week over 12 weeks, followed by a 2 mg daily maintenance dose for an additional 12 weeks. T1 weighted MRI flash sequences were performed of the face, abdomen and at mid-thigh level (MTF) at baseline, week 12, week 24 and at follow-up. Of 20 subjects who completed the 24-week study, follow-up is available for 16 patients (15 male, mean age 44.8 y, mean duration of HIV infection 13.5 y). After a median time of follow-up of 9 months, VAT remained overall 18% below baseline level (p =0.005). MTF was significantly reduced by 12% compared to its baseline level (p =0.03). Fasting glucose levels significantly improved by 21% compared to baseline (p =0.006). These results suggest that the achieved reduction of VAT using r-hGH in lipodystrophic HIV+ patients is in part maintained after a median follow-up of 9 months.
authors.affiliation: HIV Medical Treatment and Research Unit, Frankfurt, Germany. mbickel@mednet.ucla.edu
authors.forename: Markus
authors.initials: M
authors.lastname: Bickel
authors.forename: Stephan
authors.initials: S
authors.lastname: Zangos
authors.forename: Thomas
authors.initials: T
authors.lastname: Lutz
authors.forename: Johannes
authors.initials: J
authors.lastname: Eisen
authors.forename: Gabi
authors.initials: G
authors.lastname: Knecht
authors.forename: Frank D
authors.initials: FD
authors.lastname: Goebel
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Crespi
authors.forename: Volkmar
authors.initials: V
authors.lastname: Jacobi
authors.forename: Schlomo
authors.initials: S
authors.lastname: Staszewski
authors.forename: Stephan
authors.initials: S
authors.lastname: Klauke
mesh_terms: D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D050218:Body Fat Distribution; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D015497:HIV-1 / Q000472:pathogenicity*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D050152:Intra-Abdominal Fat / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies
chemical_list: D019382:Human Growth Hormone